Popular Articles
Stretch Mark Remedies

California Advocates, Lawmakers Raise Concern Over Governor's Cuts To HIV/AIDS, Health Care Services
There is growing concern among California HIV/AIDS advocates "that the Golden State will reverse course and see spikes in new HIV cases after Republican Governor Arnold Schwarzenegger this week further slashed the state Office of AIDS budget in order to deal" with a more than $20 billion deficit, the Bay Area Reporter reports (Bajko, 7/30). David Brinkman, executive director of the Desert AIDS Project in Palm Springs, which provides services to people living with HIV in the area, said, "This is the worst-case scenario cut. It"s going to cut, possibly eliminate [HIV] education" (Brambilla, Desert Sun, 7/29).
generic viagra online
Studies Examine Morning Sickness Drug, Progesterone Use To Prevent Premature Birth
The following summarizes news coverage on two pregnancy-related studies. ~ Morning sickness: The commonly prescribed heartburn drug metoclopramide -- sold generically and under the brand-names Reglan, Octamide and Maxolon -- can be used to treat morning sickness without harming the health of the fetus, according to a study published on Thursday in the New England Journal of Medicine, Time reports. The drug, which also has anti-nausea properties, is not FDA-approved for use in pregnant women in the U.S., though it is commonly prescribed in European and other countries to treat morning sickness (Park, Time, 6/10). According to the Los Angeles Times, U.S. physicians occasionally prescribe metoclopramide to treat severe morning sickness cases. The new study found that there were no statistically significant differences between infants born to women who took metoclopramide and those who did not. Researchers said that the findings "provide reassurance regarding the safety of metoclopramide for the fetus when the drug is given to women to relieve nausea and vomiting during pregnancy." The study involved 81,703 births among women enrolled in Israel"s largest health HMO, including 33,458 who used the drug (Maugh, Los Angeles Times, 6/11). Jennifer Niebyl, a professor of obstetrics and gynecology at the University of Iowa, said, "There are very few drugs approved for use in the first trimester of pregnancy. But this study could lead to metoclopramide getting approved to treat morning sickness because this is good data with big numbers" (Time, 6/10).~ Progesterone: The hormone progesterone was not effective at preventing premature births among women pregnant with twins, despite evidence suggesting its effectiveness at preventing premature births in single pregnancies, according to a University of Edinburgh study published in the journal Lancet, Reuters reports. Multiple pregnancies have a larger health risk for women and significantly increase the likelihood of miscarriage, premature birth and long-term health problems. The study involved 500 women who took either progesterone or a placebo daily for 10 weeks. Although previous studies have shown that progesterone might prevent premature birth in certain high-risk pregnancies, the new findings show the treatment did not reduce the likelihood of premature delivery or a fetus dying in utero in twin pregnancies. Twenty-five percent of women delivered or had a fetus die before 34 weeks in the progesterone group, compared with 20% in the placebo group (Kahn, Reuters, 6/10).
News of the day
Probability Of Developing Precursor Of Heart Failure Increased By 4 Risk Factors
Four well-known risk factors for heart attack significantly increased the size of the heart"s left ventricle, a key precursor of heart failure, according to a study in Circulation: Journal of the American Heart Association.
Nutrition

Second European Country To Commence Cerepro(R) Treatment On Named Patient Basis, England

Ark Therapeutics Group plc (AKT:LSE) announces that Named Patient Supply (NPS) for Cerepro® (sitimagene ceradenovec) has been approved in Finland by the National Agency for Medicines (NAM). The approval follows an application made by a neuro-surgeon in Finland for the use of Cerepro®. Finland is the second country to approve NPS, the first being France which approved NPS in February 2009. NPS is used by clinicians when patients are faced with a terminal diagnosis and to allow the use of promising unapproved therapies after existing therapy has failed. Cerepro®, Ark"s novel gene-based medicine, is being developed as an Orphan Drug for the treatment of operable malignant glioma. The product has undergone four clinical trials and demonstrated significant efficacy benefits in patients with operable malignant glioma. A Marketing Authorisation Application (MAA) for Cerepro® is currently undergoing formal review at the European Medicines Agency (EMEA) via the centralised procedure which is the standard route for all advanced therapies. Dr Nigel Parker, CEO at Ark, said: "We are very pleased to report this second NPS approval. It is encouraging to see surgeons who have experience of the drug in clinical trials wanting to use the product in normal clinical practice. Glioma is a terrible disease with a poor prognosis and as such is an area of medicine where new treatments are much needed." Malignant glioma Malignant glioma is a devastating and fatal form of brain tumour that is usually confined to the brain. The current standard therapy involves surgically removing the solid tumour mass (when possible) and initiating radiotherapy and/or chemotherapy. Even with the latest approved treatments, many patients die within one year of diagnosis, with average survival being about fourteen months. Little therapeutic progress has been made in recent years and the prognosis for malignant glioma patients is poor. A high unmet clinical need exists for new treatments that prolong life in this devastating disease. There are approximately 16,000 cases of malignant glioma in the EU which are operable. Cerepro® Cerepro® is an adenoviral mediated gene-based medicine (ad.HSV tk) given by multiple injections into the healthy brain tissue of patients following surgical removal of the solid tumour mass. In the following days, ganciclovir, is given intravenously. Once treated, healthy brain cells surrounding the site where the tumour was removed express the enzyme thymidine kinase. This converts the ganciclovir to a substance which specifically kills dividing cells. The healthy neurones surrounding the tumour in the brain are non-dividing and are therefore not susceptible to this substance. In this way Cerepro® harnesses healthy brain cells to help prevent a new tumour from growing. Ark Therapeutics Group plc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):